Acasti Pharma Inc. (ACST) CEO Jan D'Alvise on Q3 2020 Results - Earnings Call Transcript [Seeking Alpha]
Acasti Pharma, Inc. - Class A (ACST)
Last acasti pharma, inc. - class a earnings: 2/14 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
acastipharma.com/investors
Company Research
Source: Seeking Alpha
Acasti Pharma Inc. (NASDAQ: ACST Company Participants David Waldman - IR Jan D’Alvise - President and CEO Pierre Lemieux - COO, Chief Scientific Officer and Co-Founder Brian Groch - Chief Commercial Officer Jean-François Boily - VP, Finance Conference Call Participants Leland Gershell - Oppenheimer Toby Ma - Mackie Research Operator Ladies and gentlemen, Hello and thank you all for your patience and for joining today’s Acasti Pharma Third Quarter 2020 Business Update Conference Call. All participants are in a listen-only mode, but you will have an opportunity to ask questions after today’s prepared remarks. Today’s session is being recorded. And with that, I am pleased to turn the floor over to Mr. David Waldman with Investor Relations. Welcome, David. Thank you. Good afternoon, everyone and welcome to Acasti Pharma’s third quarter fiscal 2020 conference call. On the call with us this afternoon are Jan D’Alvise, President and CEO; Pierre Lemieux, Chief Operating Officer, Chief Scienti
Show less
Read more
Impact Snapshot
Event Time:
ACST
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACST alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACST alerts
High impacting Acasti Pharma, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
ACST
News
- Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business HighlightsGlobeNewswire
- Acasti Pharma Inc. (NASDAQ: ACST) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $6.00 price target on the stock.MarketBeat
- Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial [Yahoo! Finance]Yahoo! Finance
- Acasti Announces Poster Detailing its GTX-104 STRIVE-ON TrialGlobeNewswire
ACST
Earnings
- 2/12/24 - Beat
ACST
Sec Filings
- 2/13/24 - Form SC
- 2/12/24 - Form 8-K
- 2/12/24 - Form 10-Q
- ACST's page on the SEC website